Eli Lilly’s Zepbound holds possibility to dominate obesity market
Recently, Eli Lilly announced the results from its SURMOUNT-5 trial, comparing Zepbound and Wegovy’s efficacy on equal grounds
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.